NIME Next Batch PGI Quest in Delhi from 10 August to 20 August
B. Decreases vascular permeability
C. Vasoconstriction
D. Bronchodilatation
Which of the following is TRUE regarding Bradykinin?
A. Pain in inflammationB. Decreases vascular permeability
C. Vasoconstriction
D. Bronchodilatation
Ans. A. (Pain in inflammation)
Explanation
Bradykinin is a physiologically
and pharmacologically active peptide of the kinin group of proteins consisting
of nine amino acids.
•
Activation of the kinin system results in the release of the vasoactive
nonapeptide bradykinin. Bradykinin increases vascular permeability and causes
contraction of smooth muscle, dilation of blood vessels, and pain when injected
into the skin.
•
Bradykinin is a potent endothelium-dependent vasodilator, causes contraction
of non-vascular smooth muscle, increases vascular permeability and also
is involved in the mechanism of pain. In
some aspects, it has similar actions to that of histamine, and like histamine
it is released from venules rather than arterioles.
•
Bradykinin raises internal calcium levels in neocortical astrocytes causing
them to release glutamate.
• Bradykinin is also thought to be the cause of the dry cough in some patients on angiotensin converting enzyme (ACE) inhibitor drugs. This refractory cough is a common cause for stopping ACE-inhibitor therapy.
• Over activation of bradykinin is thought to play a role in a rare disease called Hereditary Angioedema, also known as Hereditary Angio-Neurotic Edema.
• Bradykinin is also thought to be the cause of the dry cough in some patients on angiotensin converting enzyme (ACE) inhibitor drugs. This refractory cough is a common cause for stopping ACE-inhibitor therapy.
• Over activation of bradykinin is thought to play a role in a rare disease called Hereditary Angioedema, also known as Hereditary Angio-Neurotic Edema.
